of the condition, however, highlights a need for more robust
prospective clinical trials exploring the few effective treatments
that have been described, as well as to investigate novel
therapies. Additionally, in assessing these studies it became
clear the limitation in evaluating for improvement of LPP lesions
with various treatments. A more standardized and validated
protocol for scoring clinical improvement in the clinical trial
setting is needed.
DISCLOSURES
The authors have no conflicts of interest of declare.
REFERENCES
1. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153(3):194-199. doi:10.7326/0003-4819-153-3-201008030-00010
2. Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol. 2010;24(5):535-540. doi:10.1111/j.1468-3083.2009.03460.x
3. Zenjari L, Elfetoiki FZ, Hali F, et al. Acide tranexamique oral dans le traitement du lichen pigmentogène [Oral tranexamic acid in the treatment of lichen planus pigmentosus: A prospective study of 20 cases]. Ann Dermatol Venereol. 2020;147(12):818-822. doi:10.1016/j.annder.2020.06.017
4. Muthu SK, Narang T, Saikia UN, et al. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55(9):1048-1054. doi:10.1111/ijd.13293
5. Shah DSD, Aurangabadkar DS, Nikam DB. An open-label non-randomized prospective pilot study of the efficacy of Q-switched Nd-YAG laser in management of facial lichen planus pigmentosus. J Cosmet Laser Ther. 2019;21(2):108-115. doi:10.1080/14764172.2018.1469770
2. Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol. 2010;24(5):535-540. doi:10.1111/j.1468-3083.2009.03460.x
3. Zenjari L, Elfetoiki FZ, Hali F, et al. Acide tranexamique oral dans le traitement du lichen pigmentogène [Oral tranexamic acid in the treatment of lichen planus pigmentosus: A prospective study of 20 cases]. Ann Dermatol Venereol. 2020;147(12):818-822. doi:10.1016/j.annder.2020.06.017
4. Muthu SK, Narang T, Saikia UN, et al. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55(9):1048-1054. doi:10.1111/ijd.13293
5. Shah DSD, Aurangabadkar DS, Nikam DB. An open-label non-randomized prospective pilot study of the efficacy of Q-switched Nd-YAG laser in management of facial lichen planus pigmentosus. J Cosmet Laser Ther. 2019;21(2):108-115. doi:10.1080/14764172.2018.1469770
AUTHOR CORRESPONDENCE
Nicole C. Syder BA nsyder@usc.edu
